Pluristem Overview
The
attached information has been prepared by Pluristem
Therapeutics, Inc. using its best efforts to
realistically and factually present the information
contained. However, subjective opinion, dependence
upon factors outside Pluristem’s control and outside
information sources unavoidably dictate that
Pluristem cannot warrant the information contained
to be exhaustive, complete or sufficient. In
addition, many factors can affect Pluristem’s plans
which could significantly alter the results intended
by Pluristem, rendering Pluristem’s plans
unattainable or substantially altered. Therefore,
interested readers should conduct their own
assessment and consult with their own professional
advisors prior to making any investment or other
decisions. Readers should also review the risk
factors set out in Pluristem’s latest 10-KSB as
filed on Edgar with the U.S. Securities and Exchange
Commission (SEC).
Pluristem
Therapeutics Inc. (NASDAQ:
PSTI; DAX: PJT) is a
bio-therapeutics
company dedicated to the commercialization of non-personalized
(allogeneic) cell therapy products for the treatment
of several severe degenerative, ischemic and
autoimmune disorders. The Company’s first product in
development, PLX-PAD, targets an annual $4
billion market and is intended to improve the
quality of life of millions of people suffering from
peripheral artery disease (PAD). The Company’s
products in development also include PLX-BMT,
which targets a $2 billion annual market and is
intended to resolve the global shortfall of matched
tissue for bone marrow transplantation (BMT);
PLX-STROKE, which targets an annual $4 billion
market and shows potential to become a new treatment
for the functional recovery from an ischemic stroke;
PLX-MS,
which targets an annual $5.4 billion market and is
intended to treat
Multiple Sclerosis; and PLX-IBD,
which targets an annual $2 billion market and is
intended to treat
patients suffering from Inflammatory Bowel Disease (IBD),
which includes Crohn’s disease and Ulcerative
Colitis. Moreover, Pluristem believes its PLX cells
are also potentially useful for other indications
such as organ transplantation, orthopedic injuries
and preventing radiation sickness.
Pluristem’s
products are derived from mesenchymal stromal cells (MSCs) obtained from the
placenta, a non-controversial, non-embryonic, source of adult stem cells. The
MSCs are then expanded in the Company’s proprietary PluriX™ 3D bioreactor.
Pluristem's products are stored "ready to use" with no matching needed and
have the potential to participate in the approximate $30 billion therapeutic and
regenerative cellular market.
The
Company’s proprietary PluriX™ 3D bioreactor imitates the natural microstructure
of bone marrow and does not require supplemental growth factors, cytokines or
other exogenous materials. Pluristem believes the resultant expanded cells,
termed PLX (PLacental eXpanded) cells, are multi-potent and able to
differentiate into a variety of cell types. Recent evidence also suggests their
efficacy may be related to their secretion of cytokines or other potent immune
modulators. Furthermore, PLX cells are immune-privileged and have
immunomodulatory properties, thus protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem has offices in the USA with research and manufacturing facilities in
Israel.
For further information, contact:
William R. Prather RPh, MD
Sr. VP Corporate Development
+1-303-883-4954
bill@pluristem.com
Press Releases :
|
|
Pluristem Therapeutics to Present at the
Noble Financial Equity Conference
More ...
|
|
|
Pluristem's PLX-MS Shows Potential Benefit
in the Prevention of Multiple Sclerosis
More ...
|
|
|
Pluristem Appoints Ms. Chaya Mazouz
Clinical Operations Director
More ...
|
|
|
The Esteemed Dr. Brian Annex Accepts
Pluristem's Invitation to Join its Scientific Advisory Board
More ...
|
